Figure 3 | Scientific Reports

Figure 3

From: Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen

Figure 3

Tamoxifen Combined with Alpelisib or Buparlisib Promotes Apoptosis. (A) Cell cycle stage was determined through flow cytometry after the treatment of MCF-7 cells with control(CTL), tamoxifen (8 µM, T), buparlisib (5 µM, BKM), alpelisib (5 µM, BYL), tamoxifen (8 µM) + buparlisib (5 µM) (T + BKM), and tamoxifen (8 µM) + alpelisib (5 µM) (T + BYL) for 24, 48, and 72 hours. (B) SubG1 proportion was quantified and depicted in a bar graph. (C) MCF-7 cells were stained for PI and annexin V after treatment for 72 hours. Flow cytometry was used to quantify each population and the results depicted as a dot plot. (D) Proportions of PI and annexin V double-positive cells. (*p < 0.05) Representative figures from the three experiments are depicted in Fig. 3.

Back to article page